Lockheed Martin Investment Management Co. Grows Stock Holdings in Pfizer Inc. $PFE

Lockheed Martin Investment Management Co. grew its position in Pfizer Inc. (NYSE:PFE) by 437.2% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 391,100 shares of the biopharmaceutical company’s stock after buying an additional 318,300 shares during the period. Lockheed Martin Investment Management Co.’s holdings in Pfizer were worth $9,965,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the company. Curio Wealth LLC grew its holdings in Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,098 shares during the last quarter. Grey Fox Wealth Advisors LLC acquired a new stake in shares of Pfizer in the 3rd quarter worth $29,000. Harbor Asset Planning Inc. purchased a new position in Pfizer during the 2nd quarter worth $29,000. Howard Hughes Medical Institute acquired a new position in Pfizer during the 2nd quarter valued at about $30,000. Finally, True Wealth Design LLC raised its stake in Pfizer by 302.5% in the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 974 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of research analyst reports. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. BMO Capital Markets reissued an “outperform” rating on shares of Pfizer in a research report on Wednesday, December 10th. Citigroup began coverage on shares of Pfizer in a report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price target for the company. Scotiabank began coverage on shares of Pfizer in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price objective for the company. Finally, Wolfe Research set a $24.00 target price on Pfizer and gave the company an “underperform” rating in a research report on Wednesday, December 17th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $27.88.

Pfizer Trading Up 0.8%

NYSE PFE opened at $26.09 on Friday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The company has a market capitalization of $148.34 billion, a PE ratio of 15.17 and a beta of 0.47. The company has a fifty day moving average of $25.39 and a 200 day moving average of $25.01.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The business had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.6%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio is currently 100.00%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.